Lubrizol Invests $60 Million to Expand Particle Sciences, Vesta & Other Facilities

The Lubrizol Corporation recently announced its LifeSciences business continues to invest in its key capabilities through a variety of planned expansions. During this latest phase, a $60-million investment will focus on new product solutions, capacity expansion, and additional cGMP manufacturing. These investments will strengthen the excipients, polymers, drug formulation and manufacturing, and medical device contract manufacturing capabilities at Lubrizol LifeSciences’ global facilities.

Commercial drug product manufacturing will be added at the company’s Particle Sciences facility in Bethlehem, PA. Leveraging the company’s knowledge in complex formulations and production, the facility will be adjacent to the existing development and clinical trial manufacturing site, offering customers a seamless flow from development through manufacturing. This new space, which is expected to be operational in the fourth quarter of 2017, will accommodate both sterile and non-sterile products, highly potent compounds, and organic solvent processing.

Additionally, LifeSciences is investing to expand its global facilities for excipients, polymers, and contract manufacturing, with a focus on quality and efficiency. This capital investment will impact multiple sites to increase in-house engineering capacity across the LifeSciences portfolio of medical and pharmaceutical applications. This includes new investments in design, manufacturing, and sterilization technologies for the production of interventional catheters and long-term implantable devices, an area of strategic importance to the medical device segment.

“We have significantly enhanced our capabilities through the combination of strong polymer technology, application know-how, and world-class manufacturing,” states Deb Langer, Vice President, Lubrizol Personal Home and Health Care. “As healthcare companies look for total solution providers, we continue to invest in the right areas to provide valuable offerings where our customers are experiencing the most growth.”

Lubrizol LifeSciences links science to life. An in-depth understanding of functional polymer systems, combined with a portfolio of specialty materials, enables LifeSciences to deliver application-specific, quality solutions to the medical device and pharmaceutical industries. The combination of our polymer expertise, drug formulation development and quality contract manufacturing allows LifeSciences to offer our customers end-to-end solutions for success in the drug delivery market.

The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers’ products while reducing their environmental impact. It is a leader at combining market insights with chemistry and application capabilities to deliver valuable solutions to customers in the global transportation, industrial and consumer markets. Lubrizol improves lives by acting as an essential partner in our customers’ success, delivering efficiency, reliability or wellness to their end users. Technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care, personal care and skin care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions.

With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,300 employees worldwide. Revenues for 2016 were $6.5 billion. For more information, visit www.Lubrizol.com.

Media Contact

Maureen Grieco
Maureen.grieco@particlesciences.com
(610) 861-4701